首页> 外文期刊>Cancer immunology research. >Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors
【24h】

Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors

机译:在近红外线光疗法后宿主免疫力通过PD-1检查点封闭式封闭来消除已建立的抗原肿瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Near-infrared photoimmunotherapy (NIR-PIT) induces immunogenic cell death but has mostly failed to induce durable antitumor responses in syngenic tumor mouse models. We hypothesized that adaptive immune resistance could be limiting durable responses after treatmemt with NIR-PIT. We investigated the effects of combining NIR-PIT targeting cell-surface CD44 and PD-1 blockade in multiple syngeneic tumor models. In two of three models, NIR-PIT monotherapy halted tumor growth, enhanced dendritic cell tumor infiltration, and induced de novo tumor antigen-specific T-cell responses absent at baseline. The addition of PD-1 blockade reversed adaptive immune resistance, resulting in both enhanced preexisting tumor antigen-specific T-cell responses and enhanced de novo T-cell responses induced by NIR-PIT. Enhanced immune responses correlated with shared tumor antigen expression, suggesting that antigenicity is a major determinant of response to combination NIR-PIT and PD-1 blockade. Combination treatment induced complete rejection of MC38 tumors treated with NIR-PIT, as well as untreated, distant tumors. Accordingly, tumor antigen-specific T-cell responses were measured in both treated and untreated tumors, validating the development of systemic antitumor immunity. Mice that cleared tumors resisted subsequent tumor challenge, indicating the presence of systemic immune memory. Cumulatively, these results demonstrate reversal of adaptive immune resistance following induction of innate and adaptive immunity by NIR-PIT, resulting in high rates of tumor rejection and/or significant tumor growth control in antigenic syngeneic models of cancer.
机译:近红外线光疗法(NIR-PIT)诱导免疫原性细胞死亡,但大多数未能诱导生成肿瘤小鼠模型中的耐用抗肿瘤反应。我们假设自适应免疫抗性可能在用尼拉坑治疗后限制耐用的反应。我们研究了在多种同工肿瘤模型中组合NIR-PIT靶向细胞表面CD44和PD-1阻断的影响。在三种模型中的两个中,Nir-Pit单疗法停止了肿瘤生长,增强的树突细胞肿瘤浸润,并且诱导了在基线上不存在的Novo肿瘤抗原特异性T细胞反应。添加PD-1阻断反转的自适应免疫抗性,导致增强的预先存在的肿瘤抗原特异性T细胞反应和增强的NiR-in诱导的Novo T细胞应答。增强的免疫应答与共同肿瘤抗原表达相关,表明抗原性是对NIR-PIT和PD-1阻断的反应的主要决定因素。组合治疗诱导完全抑制用NiR-坑处理的MC38肿瘤,以及未处理的远处肿瘤。因此,在治疗和未处理的肿瘤中测量肿瘤抗原特异性T细胞应答,验证了系统性抗肿瘤免疫的发展。清除肿瘤的小鼠抵抗随后的肿瘤攻击,表明存在全身免疫记忆。累积地,这些结果证明了NIR-PIT诱导先天和适应性免疫后的适应性免疫抗性的逆转,导致癌症抗原同工模型中的肿瘤排斥和/或显着的肿瘤生长控制。

著录项

  • 来源
    《Cancer immunology research.》 |2019年第3期|共13页
  • 作者单位

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

    Natl Inst Deafness &

    Other Commun Disorders Translat Tumor Immunol Program NIH Bethesda MD USA;

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

    Natl Inst Deafness &

    Other Commun Disorders Translat Tumor Immunol Program NIH Bethesda MD USA;

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

    Natl Inst Deafness &

    Other Commun Disorders Translat Tumor Immunol Program NIH Bethesda MD USA;

    NCI Mol Imaging Program Ctr Canc Res NIH Bethesda MD 20892 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号